Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Current Taxes (2019 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Current Taxes for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Current Taxes rose 3.34% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 3.34% year-over-year, with the annual reading at $1.2 million for FY2025, 3.34% up from the prior year.
  • Current Taxes hit $1.2 million in Q4 2025 for Ligand Pharmaceuticals, down from $1.3 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $11.4 million in Q2 2023 to a low of $305000.0 in Q2 2025.
  • Historically, Current Taxes has averaged $3.3 million across 4 years, with a median of $1.8 million in 2025.
  • Biggest YoY gain for Current Taxes was 201.08% in 2023; the steepest drop was 87.59% in 2023.
  • Year by year, Current Taxes stood at $9.7 million in 2022, then crashed by 87.59% to $1.2 million in 2023, then decreased by 0.42% to $1.2 million in 2024, then rose by 3.34% to $1.2 million in 2025.
  • Business Quant data shows Current Taxes for LGNDZ at $1.2 million in Q4 2025, $1.3 million in Q3 2025, and $305000.0 in Q2 2025.